Cryoport 10-Q Details Q3 Loss, Positive 9-Month Cash Flow and December Note Repayment
CYRX has more than doubled off its 52-week low of $7.61 on elevated volume (2.2× avg).
Summary
Cryoport's Q3 10-Q shows a $10.9 million net loss on $50.2 million of revenue, positive $10.1 million nine-month operating cash flow, and $393.1 million of liquidity against $186.2 million of convertible notes due in December 2026 that management intends to repay from cash.
Key Events · Earnings and Guidance · CYRX
-
Q3 Revenue Up 14% to $50.2M
Total revenue rose to $50.2 million from $44.2 million, with Life Sciences Services up 17.8% to $28.6 million and Life Sciences Products up 8.4% to $21.7 million.
-
Q3 Net Loss of $10.9M
Net loss was $10.9 million, or $0.25 per share attributable to common stockholders after a $2.0 million paid-in-kind preferred dividend, versus a $6.9 million loss a year earlier.
-
Nine-Month Operating Cash Flow Turns Positive
Operating activities generated $10.1 million for the nine months ended September 30, 2026, versus $9.5 million used in the prior-year period.
-
$186.2M Convertible Notes Due December 2026
The 0.75% convertible senior notes mature in December 2026; management intends to repay the $186.2 million principal from the $393.1 million of cash, cash equivalents and short-term investments on hand.
Analysis · CYRX · Life Sciences
The headline numbers were already out today, but the full 10-Q fills in what the press release did not: a $10.9 million Q3 net loss and $12.9 million attributable to common holders ($0.25 per share), plus a swing to $10.1 million of operating cash inflow for the first nine months versus a $9.5 million outflow a year earlier. The balance sheet is the real story — $393.1 million of cash and short-term investments against $186.2 million of 0.75% convertible notes due in December 2026, which management says it will repay from existing liquidity. That removes refinancing risk and leaves roughly $207 million of liquidity, but it also consumes over half the cash pile. Gross margin slipped to 47.5% from 48.2% on a mix shift toward lower-margin aluminum dewars, so the 14% revenue growth is not flowing through at full rate.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CYRX was trading at $17.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $812.9M. The 52-week trading range was $7.61 to $18.88. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.